121 related articles for article (PubMed ID: 32536689)
41. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
43. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Barosi G; Viarengo G; Pecci A; Rosti V; Piaggio G; Marchetti M; Frassoni F
Blood; 2001 Dec; 98(12):3249-55. PubMed ID: 11719361
[TBL] [Abstract][Full Text] [Related]
45. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
[TBL] [Abstract][Full Text] [Related]
46. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
47. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
48. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
49. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.
Shi J; Zhao Y; Ishii T; Hu W; Sozer S; Zhang W; Bruno E; Lindgren V; Xu M; Hoffman R
Cancer Res; 2007 Jul; 67(13):6417-24. PubMed ID: 17616702
[TBL] [Abstract][Full Text] [Related]
50. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
[TBL] [Abstract][Full Text] [Related]
51. High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.
Hasselbalch HC; Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA
Leuk Res; 2011 Oct; 35(10):1330-4. PubMed ID: 21470677
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis.
Wang J; Xu J; Gale RP; Xu Z; Li B; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Qu S; Zhang P; Xiao Z
Leuk Res; 2014 Oct; 38(10):1207-11. PubMed ID: 25182689
[TBL] [Abstract][Full Text] [Related]
53. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA; Verstovsek S; Cervantes F; Barosi G; Reilly JT; Dupriez B; Levine R; Le Bousse-Kerdiles MC; Wadleigh M; Campbell PJ; Silver RT; Vannucchi AM; Deeg HJ; Gisslinger H; Thomas D; Odenike O; Solberg LA; Gotlib J; Hexner E; Nimer SD; Kantarjian H; Orazi A; Vardiman JW; Thiele J; Tefferi A;
Leuk Res; 2007 Jun; 31(6):737-40. PubMed ID: 17210175
[TBL] [Abstract][Full Text] [Related]
54. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.
Lucijanic M; Mitrovic Z; Cicic D; Prka Z; Pejsa V; Livun A; Stoos-Veic T; Romic Z; Zivkovic M; Lucijanic I; Fabris Z; Kusec R
Int J Hematol; 2018 Feb; 107(2):166-172. PubMed ID: 29022201
[TBL] [Abstract][Full Text] [Related]
55. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
56. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
57. [Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis].
Wu JY; Li B; Jia YJ; Zhang PH; Xu ZF; Qin TJ; Qu SQ; Pan LJ; Liu JQ; Yan X; Zhang YD; Chen J; Gong JY; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):989-995. PubMed ID: 33445845
[No Abstract] [Full Text] [Related]
58. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
59. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2012 Jan; 53(1):123-9. PubMed ID: 21806350
[TBL] [Abstract][Full Text] [Related]
60. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
